Your browser doesn't support javascript.
loading
Lower BAFF Levels in Myasthenic Patients Treated with Glucocorticoids.
Sobieszczuk, Ewa; Szczudlik, Piotr; Kubiszewska, Justyna; Szyluk, Beata; Lipowska, Marta; Dutkiewicz, Malgorzata; Kostera-Pruszczyk, Anna.
Afiliación
  • Sobieszczuk E; Department of Neurology, Medical University of Warsaw, Banacha 1a, 02-097, Warsaw, Poland.
  • Szczudlik P; Department of Neurology, Medical University of Warsaw, Banacha 1a, 02-097, Warsaw, Poland. pszczudlik@wum.edu.pl.
  • Kubiszewska J; Department of Neurology, Medical University of Warsaw, Banacha 1a, 02-097, Warsaw, Poland.
  • Szyluk B; Department of Neurology, Medical University of Warsaw, Banacha 1a, 02-097, Warsaw, Poland.
  • Lipowska M; Department of Neurology, Medical University of Warsaw, Banacha 1a, 02-097, Warsaw, Poland.
  • Dutkiewicz M; Department of Immunology, Biochemistry and Nutrition, Medical University of Warsaw, Warsaw, Poland.
  • Kostera-Pruszczyk A; Department of Neurology, Medical University of Warsaw, Banacha 1a, 02-097, Warsaw, Poland.
Arch Immunol Ther Exp (Warsz) ; 69(1): 22, 2021 Aug 02.
Article en En | MEDLINE | ID: mdl-34338918
B-cell activating factor (BAFF), a member of tumor necrosis factor family, activates B cells, promotes their survival and proliferation. BAFF is considered to have an influence on development of autoimmune diseases including myasthenia gravis (MG). We aimed to evaluate BAFF serum levels in MG patients, their potential connection with therapy and course of MG. Cross-sectional study. Two hundred eighteen adult patients with MG (67% women, age: 18-89 years, 82.6% AChR antibody seropositive (AChRAb(+)). Serum BAFF levels, their relationship with severity of clinical symptoms, therapy conducted, clinical and demographic features and other factors were analyzed. Patients with AChRAb(+) MG demonstrated significantly higher BAFF levels than MuSK-MG patients (831.2 ± 285.4 pg/ml vs. 745.6 ± 633.4 pg/ml, respectively; p = 0.030). Serum BAFF levels in women were significantly higher than in men (855.9 ± 302.5 vs. 756.6 ± 289.4, respectively; p = 0.017). Mean serum BAFF level was significantly decreased in patients who were ever treated with corticosteroids (CS) (770.4 ± 327.8 pg/ml vs. 891.3 ± 246.1 pg/ml, respectively; p = 0.001). Thymoma-MG patients demonstrated significantly lower BAFF levels (671.2 ± 244.9 vs. 833.5 ± 302.4, respectively; p = 0.044). Thymectomized patients did not differ in BAFF levels from the MG patients who had not undergone thymectomy. In multiple linear regression model, recent CS therapy and male sex were found to be independent predictors of lower BAFF levels. Serum BAFF level is decreased in patients treated with CS, which may suggest inhibiting influence of CS on BAFF-a potential mechanism contributing to the effectiveness of such therapy.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias del Timo / Miastenia Gravis Tipo de estudio: Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Límite: Adolescent / Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Arch Immunol Ther Exp (Warsz) Año: 2021 Tipo del documento: Article País de afiliación: Polonia Pais de publicación: Suiza
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias del Timo / Miastenia Gravis Tipo de estudio: Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Límite: Adolescent / Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Arch Immunol Ther Exp (Warsz) Año: 2021 Tipo del documento: Article País de afiliación: Polonia Pais de publicación: Suiza